Today #LCSM received the following information about a lung cancer grant opportunity from The CHEST Foundation (the philanthropic arm of the American College of Chest Physicians). We’re sharing it here to encourage more participation in lung cancer research.
The CHEST Foundation has been supporting lung cancer research since 2002, and this award, established in 2011, funds much needed research that leads to improved treatment and/or a cure for lung cancer. The grant recipient will receive $100,000 in payments of $50,000 each year for 2 years. Eligibility criteria and the application are available online.
For patients and families, our foundation has free lung cancer patient education information available.
The next #LCSM Chat will occur Thursday April 10 at 8 PM EDT (5 PM PDT) and will focus on “Exercise During and After Lung Cancer Treatment.” Our moderator will be Janet Freeman-Daily.
Exercise is known to improve quality of life and reduce recovery time, fatigue, sleep issues and depression in cancer patients. A recent study indicates high-intensity exercise during cancer treatment can have many benefits. Some facilities now offer pulmonary rehabilitation after lung cancer treatment to help patients recover lung capacity more quickly. Others offer fitness classes that adapt a fitness program based on the cancer survivor’s individual health situation. Even walking a bit each day can make a difference.
We’ll use these topics to stimulate the conversation:
- T1: What kinds of exercise and rehab activities are helpful during and/or after lung cancer treatment?
- T2: How can lung cancer patients learn about exercise and pulmonary rehabilitation options?
- T3: How can caregivers, family members and healthcare providers encourage a lung cancer patient to exercise without “pushing”?
Guidelines on how to participate in an #LCSM Chat can be found on the “#LCSM Chat” page of the #LCSM website. Hope to see you on Twitter!
Cure Magazine: Lung Cancer and Exercise?
“…exercise may also have important benefits for lung cancer patients and survivors, regardless of disease stage or limited physical activity, also called “de-conditioning,” which can cause the heart and muscles to regress and become less efficient.”
University of Colorado Hospital: Pulmonary Rehab Helps Patients Battle Back from Lung Disease
“The goal is to help patients recover as much as of their lung capacity as possible. That not only improves their quality of life; it helps prevent return trips to the hospital. ‘Physical reconditioning is the biggest part of recovery,’ ….”
Exercise for the management of cancer-related fatigue in adults (PubMed)
“…aerobic exercise can be regarded as beneficial for individuals with cancer-related fatigue during and post-cancer therapy, specifically those with solid tumours.”
High-Intensity Exercise Best During Lung Cancer Therapy (Medscape)
“High-intensity exercise during treatment for nonsmall-cell lung cancer can be more effective than the same program after cancer treatment”
Physical activity preferences of early-stage lung cancer survivors (PubMed)
“The majority of participants reported a desire for physical activity advice and a willingness to engage in physical activity.”
Upcoming #LCSM Chat, Thursday, March 27 at 5 pm PT, 8 pm ET: Should All Targeted Rx Lung Cancer Trials be Biomarker-Selective?
ASCO, the American Society for Clinical Oncology, is promoting a new principle that targeted therapies should be used only in targeted patients, as part of a general trend that we need to move away from trials that test new non-chemotherapy agents in a broad population. Meanwhile, we’ve just recently seen a few high profile negative trials in the last few weeks, such as the large phase III METLung trial of “METMAb” or onartuzumab, the monoclonal antibody against the target MET (mesenchymal epithelial transition), combined with Tarceva (erlotinib), and also the MAGE-A3 vaccine in the MAGRIT trial done as adjuvant treatment for resected non-small cell lung cancer.
Increasingly, our negative trials are followed by subset analyses that identify a potential subgroup that may be significant beneficiaries, often offset by larger groups that don’t benefit or are even harmed. As an example, the MAGRIT trial was just reported as negative in the broad population, but the study is still looking at an investigational gene signature that may predict for significant benefit vs. non-benefit with the MAGE-A3 vaccine.
If our large randomized trials, requiring hundreds to thousands of patients and costing millions of dollars and years to conduct, are extremely likely to return as negative and require a more refined population with a prospectively defined target, how should we conduct trials of targeted therapies in lung cancer? With that in mind, these are the questions we’ll tackle in our upcoming #LCSM chat on Thursday, March 27th, at 8 PM ET, 5 PM PT:
1) Do we need to identify a target before committing people, money, & time to large lung cancer trials? Should we abandon targeted therapy trials in broad populations?
2) Is tissue for testing and molecular testing widely available enough today to limit targeted therapy trials, or will too many potential patients miss out? Will this be a hurdle to access?
3) Will those without any “targetable markers” be left without trial options? Will we exclude too many “molecular marker orphans”?
We need insights from people running trials, who would enroll patients on trials, and those seeking trial options. We hope you’ll join us for a lively tweet chat, moderated by Dr. H. Jack West, Thursday evening.
Just check out http://www.tchat.io/rooms/lcsm at the appointed hour, or use the twitter client of your choice and follow the hashtag #LCSM. Hope to see you then!